Final-Program-ATS-2023-AP.vp

112

SUNDAY • MAY 21

2:27 Distinct Plasma and Lower Respiratory Tract Biomarker Profiles During Acute Respiratory Failure/ C. Caglayan, Pittsburgh, PA 2:39 Macrophage TRPV4 Protects Against Bacterial Pneumonia-induced Lung Injury Through the NF- k B Pathway/ R.G. Scheraga, Cleveland, OH 2:51 Aerosolized aCT1 Peptide Reduces SARS-CoV-2 Induced Lung Injury in the Syrian Hamster/ M. Bowler, Mount Pleasant, SC 3:03 Myeloid STAT1 Regulates Injury Response During Hemorrhagic Alveolar Damage/ A.P. Gheware, Pittsburgh, PA 3:15 A Lysine Demethylase, Kdm6b, Contributes to Treg Function During Influenza-induced Lung Injury/ J.R. Mock, Chapel Hill, NC 3:27 Small Extracellular Vesicles From MSC-NTF Cells Induce Significant Improvement in Inflammatory Lung Disease Models/ H. Kaspi, Petach Tikva, Israel 3:39 The Role of Overdistension and Recruitment/Derecruitment on Alveolar Inflammation and Injury/ S. Blair, Syracuse, NY 3:51 A Novel Non-catalytic p38alpha/MK2 Pathway Modulator Mitigates Acute Lung Injury and Improves Survival in a Mouse Influenza Model/ J.D. Hasday, Baltimore, MD 4:03 Alveolar Macrophage Subsets Are Dynamic and Associated With Mortality in the Acutely Injured Lung/ E.D. Morrell, Seattle, WA

3:00 Introduction to Debate 3: Senolytics in Respiratory Diseases M. Rojas, MD, Columbus, OH 3:02 Truth: Senolytics Can Be Effective in Fibroproliferative and Other Respiratory Diseases A.M. Nambiar, MD, MSCR, San Antonio, TX 3:11 Myth: Senolytics Can Be Effective in Fibroproliferative and Other Respiratory Diseases B. Crestani, MD, PhD, Paris, France 3:20 Summary and Audience Response Results (Debate 3) M. Rojas, MD, Columbus, OH 3:22 Introduction to Debate 4: PEEP and Oxygenation in ARDS A.M. Esper, MD, MS, ATSF, Atlanta, GA 3:24 Truth: PEEP Titration in ARDS Should Prioritize Arterial Oxygenation S. Sahetya, MD, MHS, Baltimore, MD 3:33 Myth: PEEP Titration in ARDS Should Prioritize Arterial Oxygenation J. Beitler, MD, MPH, New York, NY 3:42 Summary and Audience Response Results (Debate 4 and Overall Session) A.M. Esper, MD, MS, ATSF, Atlanta, GA This session and the International Conference are supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BEHAVIORAL • CLINICAL MINI SYMPOSIUM

BASIC • CLINICAL • TRANSLATIONAL MINI SYMPOSIUM

A94

ADVANCES IN HEALTH SERVICES RESEARCH FOCUSED ON INTERSTITIAL LUNG DISEASE AND CYSTIC FIBROSIS

A93

MECHANISTIC INSIGHTS AND NOVEL THERAPEUTICS IN ACUTE LUNG INJURY

2:15 p.m. - 4:15 p.m.

Walter E. Washington Convention Center Room 152 A-B (Street Level)

2:15 p.m. - 4:15 p.m.

Walter E. Washington Convention Center Room 143 A-C (Street Level)

Chairing: M. Sharp, MD, MHS, Baltimore, MD K.J. Ramos, MD, MS, Seattle, WA L. Fidler, MD, MSci, Toronto, Canada Oral Presentations: 2:15 Prescribing Patterns of Antifibrotics in Patients Diagnosed With Idiopathic Pulmonary Fibrosis/ D. Shankar, Boston, MA 2:27 Comparative Effectiveness of Nintedanib and Pirfenidone in Patients Diagnosed With Idiopathic Pulmonary Fibrosis/ D. Shankar, Boston, MA

Chairing: F.T. Korkmaz, PhD, Worcester, MA C. Mikacenic, MD, Seattle, WA

J.M. Sturek, MD, PhD, Charlottesville, VA H.S. Kulkarni, MD, MSc, ATSF, Saint Louis, MO

Oral Presentations: 2:15 CD177+ Neutrophils Produce Neutrophil Extracellular Traps to Promote Lung Ischemia Reperfusion Injury/ C. Li, Shanghai, China

ATS 2023 • Washington, DC